• print
  • mail
  • Home
  • Media
  • In the News

  • Overview
  • Fact Sheets
  • Featured Content
  • News Releases
  • Our Perspective
  • Social Media
  • Media Contacts
  • In the News
  • Corporate News
  • Biosimilars in the News
  • Pipeline in the News
  • Enbrel® in the News
  • ESAs in the News
  • Prolia® in the News
  • Neulasta® in the News
  • Nplate® in the News
  • Sensipar® in the News
  • Vectibix® in the News
  • XGEVA™ in the News
  • Virtual Press Kits
In the News
 Corporate News
Apr. 16, 2012
Amgen Executes Civil Settlement Agreement for Federal Case in South Carolina
Nov. 1, 2012
Amgen Supports Assistance For Patients Affected By Hurricane Sandy
Oct. 25, 2012
Amgen and Kleiner Perkins Caufield & Byers Partner to Create New Spin-Out Biotech Company

more >

Biosimilars in the News
Apr. 22, 2013
Amgen Welcomes European Commission Report on EU Biosimilars Uptake
Mar. 24, 2013
Amgen Supports World Health Organization’s Proposed Distinguishable Naming Policy for Biosimilars
Sept. 28, 2012
Amgen Statement on EMA Revised Biosimilars Q&A

Background Documents

Learn more about biosimilars

more >

Enbrel® (etanercept) in the News
Jan. 16, 2013
Amgen Statement on Stroke Research
Apr. 24, 2009
Amgen and Wyeth announce ENBREL Support™ Program
Mar. 18, 2009
Amgen Statement on Alzheimer's Case Study

Background Documents

Prescribing information for Enbrel®

more >

ESAs in the News
Sep. 01, 2011
Amgen Statement on Proposed Changes to the Quality Incentive Program in Dialysis
Jun. 24, 2011
Amgen Posts Modified ESA Labeling
Jan. 19, 2011
Amgen Presents at MEDCAC Meeting on ESAs in Chronic Kidney Disease

Background Documents

Prescribing information for Aranesp®
Prescribing information for EPOGEN®

more >

Pipeline in the News
May 15, 2013
Amgen at ASCO 2013
Nov. 5, 2012
Amgen at AHA Scientific Sessions 2012
May 16, 2012
Amgen at ASCO 2012

more >

Prolia® (denosumab) in the News
Sep. 20, 2012
Press Release: FDA Approves New Indication For Prolia® (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture
Sep. 20, 2012
Amgen Modifies U.S. Prescribing Information for Prolia® (denosumab)
Sep. 20, 2012
Amgen Modifies Prolia® Risk Evaluation and Mitigation Strategy (REMS) Materials (US)

Background Documents

Prescribing information for Prolia®

more >

Neulasta® (pegfilgrastim) in the News
June 19, 2009
Amgen Introduces Neulasta FIRST STEP™ Program

Background Documents

Prescribing information for Neulasta®

more >

Nplate® (romiplostim) in the News
Dec. 6, 2011
Amgen and FDA Agree to Modify Nplate® Risk Evaluation and Mitigation Strategy
Jul. 27, 2011
Amgen Modifies U.S. Prescribing Information for Nplate® (romiplostim)

Background Documents

Prescribing information for Nplate®

more >

Sensipar® (cinacalcet) in the News
Feb. 19, 2013
Letter to Healthcare Professionals

Background Documents

Prescribing information for Sensipar®

more >

Vectibix® (panitumumab) in the News

Apr. 17, 2013
Amgen Statement on Additional Biomarker Analysis Beyond KRAS From Completed Phase 3 Study
Sep. 14, 2012
Amgen Modifies U.S. Prescribing Information for Vectibix® (panitumumab)
Jan. 12, 2012
Amgen Modifies U.S. Prescribing Information for Vectibix® (panitumumab)

Background Documents

Prescribing information for Vectibix®

more >

XGEVA™ (denosumab) in the News
June 8, 2012
Amgen Modifies U.S. Prescribing Information for XGEVA® (denosumab)
May 2, 2012
Amgen Modifies U.S. Prescribing Information for XGEVA® (denosumab)
Apr. 27, 2012
Amgen Modifies U.S. Prescribing Information for XGEVA® (denosumab)

Background Documents

Prescribing Information for XGEVA® (denosumab) (US)

 


  • Related Links
  • Products
  • Pipeline
  • Corporate Citizenship
  • Locations
footer